Iron’s Dark Side: How Ferroptosis Drives Brain Disease and What Could Stop It

Neurological disorders remain among the most stubborn challenges in modern medicine, robbing millions of people of memory, movement, and independence while disease-modifying therapies stay stubbornly out of reach. Now a comprehensive review published in the Journal of Translational Medicine by Wenzheng Yuan, Wenjing Jia, and Quan Wang of Nanjing University of Aeronautics and Astronautics offers a unifying explanation for why neurons die in Alzheimer’s disease, Parkinson’s disease, and stroke, and it centers on a form of cell death that has captivated biologists since its discovery barely a decade ago: ferroptosis. Unlike apoptosis, the tidy, programmed dismantling of a cell, ferroptosis is an iron-dependent catastrophe in which lipid membranes are oxidized and rupture, spilling inflammatory contents into surrounding tissue. The review argues that the brain is uniquely, almost exquisitely, vulnerable to this process, and that understanding why could finally unlock therapies for diseases that have resisted decades of drug development.

The authors introduce what they call the Iron-Brain Nexus, an integrative framework that links regional iron metabolism in the brain with the nervous system’s distinctive metabolic profile. Three features of neural tissue stand out. First, neurons and their supporting glial cells are extraordinarily rich in polyunsaturated fatty acids, the very molecules whose bis-allylic hydrogen bonds make them preferred substrates for the free-radical chain reactions that drive lipid peroxidation. Second, the brain consumes a disproportionate share of the body’s oxygen to fuel its relentless oxidative metabolism, generating a steady stream of reactive oxygen species as a byproduct of mitochondrial respiration. Third, compared with the liver or other iron-handling organs, the nervous system has a comparatively limited antioxidant reserve. Put these three ingredients together with a steady supply of redox-active iron, and the brain becomes a kind of chemical reactor primed for ferroptosis, with certain neuronal populations sitting closest to the detonator.

Iron is not a contaminant in the brain; it is essential. It powers the iron-sulfur clusters of mitochondrial respiratory complexes, supports myelin synthesis, and serves as a cofactor for enzymes that synthesize the neurotransmitters dopamine and serotonin. The review details how iron is imported across the blood-brain barrier, shuttled by transferrin and its receptor, released into a tightly buffered labile iron pool, and stored in ferritin when not in use. Export depends on ferroportin, working alongside ceruloplasmin and hephaestin to oxidize iron into a form suitable for transport. When this choreography falters, iron accumulates. The ferritinophagy pathway, in which the cargo receptor NCOA4 delivers ferritin to autophagosomes for degradation, can flood the labile iron pool on demand, and heme oxygenase-1 liberates iron from heme during inflammatory stress. Each of these control points, the authors emphasize, is a potential switch that tips vulnerable neurons from healthy metabolism into ferroptotic collapse.

The molecular engine of ferroptosis is the failure of the glutathione peroxidase 4 system. GPX4 is the only enzyme capable of reducing lipid hydroperoxides embedded in membranes back to harmless lipids, and it depends on a continuous supply of glutathione. That supply hinges on the cystine/glutamate antiporter known as system xc-, encoded in part by SLC7A11, which imports cystine that cells convert to cysteine. Block the transporter, deplete glutathione, or inhibit GPX4 directly, and lipid peroxides accumulate until membranes disintegrate. The brain has backup systems, including ferroptosis suppressor protein 1, which uses CoQ10 to quench radical chains at the plasma membrane, and dihydroorotate dehydrogenase, which protects mitochondria, but these redundancies are finite. Enzymes such as ACSL4 and LPCAT3 determine which fatty acids get incorporated into phospholipids, effectively deciding how flammable a neuron’s membranes are, while lipoxygenases act as the matchsticks that initiate peroxidation.

Applying this framework to Alzheimer’s disease, the review distinguishes well-supported mechanisms from emerging, more speculative findings. Iron deposits co-localize with amyloid-beta plaques, and amyloid precursor protein processing is itself sensitive to iron levels, creating a feedback loop in which plaque-associated iron promotes the very oxidative damage that worsens pathology. The apolipoprotein E4 allele, the strongest genetic risk factor for late-onset Alzheimer’s, is linked to altered lipid handling and heightened ferroptotic susceptibility. Markers of lipid peroxidation, such as 4-hydroxynonenal adducts, are abundantly documented in affected brain regions, and studies of GPX4 loss and glutathione depletion in models of the disease reinforce the connection, although the authors caution that causality in human tissue remains harder to establish than correlation.

Parkinson’s disease presents perhaps the most striking case for the Iron-Brain Nexus. The dopaminergic neurons of the substantia nigra, the cells that die in Parkinson’s, are almost a textbook setup for ferroptosis: they handle dopamine, a molecule prone to oxidative chemistry; they rely on neuromelanin, which binds iron; and postmortem studies consistently show elevated iron in the degenerating substantia nigra. Dopamine metabolism generates reactive quinones and hydrogen peroxide, and tetrahydrobiopterin, the cofactor for dopamine synthesis, also feeds the GPX4 repair pathway, tying neurotransmitter biochemistry directly to ferroptotic defense. In stroke, the picture shifts to ischemia-reperfusion injury, where the sudden restoration of blood flow unleashes a burst of reactive oxygen species, releases iron from damaged mitochondria, and depletes glutathione, making ferroptosis a major executor of the delayed cell death that expands the infarct core after the initial insult.

What makes the review timely is its sober assessment of the therapeutic landscape. Iron chelators such as deferoxamine have shown promise in experimental models and early clinical studies, but removing iron systemically risks anemia and other deficiencies, and delivering chelators across the blood-brain barrier at effective concentrations remains a formidable obstacle. Lipid peroxidation inhibitors, including the experimental compounds ferrostatin-1 and liproxstatin-1, potently block ferroptosis in cell culture and animal studies, yet their chemical instability and pharmacokinetics have limited clinical translation. Antioxidant strategies that bolster glutathione or mimic CoQ10 face similar delivery challenges, while gene-targeted approaches aiming to upregulate NRF2-driven antioxidant defenses or modulate ACSL4 expression are still at the conceptual stage. The authors stress that target specificity and neuronal safety are as important as potency; a drug that prevents ferroptosis but disrupts normal iron-dependent neurotransmitter synthesis would trade one pathology for another.

The translational challenges the review catalogues are not trivial. The blood-brain barrier excludes the large majority of drug candidates, and ferroptosis-targeting molecules are no exception. Biomarkers represent another gap: measuring lipid peroxidation or the labile iron pool in a living human brain is currently impractical, forcing researchers to rely on indirect imaging of iron deposition or fluid markers that may not reflect what is happening inside neurons. The authors argue that biomarker-informed therapeutic development, guided by the Iron-Brain Nexus framework, is the most rational path forward, allowing trials to enroll patients whose disease actually involves ferroptotic mechanisms and to monitor whether candidate drugs engage their targets. Stratifying patients by genetic risk factors such as APOE4 or by imaging-based iron burden could dramatically improve the chances of detecting a treatment effect.

Perhaps the most important contribution of the work is its insistence on evidence hierarchy. In a field moving at breakneck speed, with thousands of ferroptosis papers published annually, the review separates mechanisms validated across multiple models and human tissue from findings that rest on a single experiment or indirect correlation. That discipline matters because ferroptosis inhibitors are already being proposed as treatments for conditions as varied as glioblastoma, where inducing ferroptosis in tumor cells is the goal, and neurodegeneration, where protecting neurons from it is the aim. The same biology points in opposite directions depending on context, and the brain’s peculiar metabolic architecture determines which way the scales tip. As the authors conclude, the Iron-Brain Nexus offers more than a summary; it is a roadmap for deciding which interventions, in which diseases, at which disease stages, are most likely to succeed, turning a decade of fundamental discovery into a concrete agenda for clinical translation.

Subject of Research: Iron-dependent ferroptotic cell death and its role in neurological disease and therapy

Article Title: Ferroptosis in the nervous system: metabolic regulation, iron homeostasis, and translational therapeutic strategies

Article References: Yuan, W., Jia, W., & Wang, Q. (2026). Ferroptosis in the nervous system: metabolic regulation, iron homeostasis, and translational therapeutic strategies. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09063-4

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09063-4

Keywords: ferroptosis, iron homeostasis, neurodegeneration, Alzheimer's disease, Parkinson's disease, stroke, lipid peroxidation, GPX4, glutathione, blood-brain barrier, iron chelation, brain metabolism